To Biovie Or Not To Biovie- In the Wake of Unusual Alzheimer’s Trial Results
I have a few shares of a tiny biotech called Biovie(BIVI) that got much tinier this morning after they released results of a phase 3 Alzheimer’s trial for their NE3107 drug candidate. Trial failures are normal, they happen, and it’s why I have for many years bought biotechs in baskets. However, the company’s announcement of trial results is… Read More »